Caplin Point Laboratories Limited
NSE: CAPLIPOINT
NSE
1,906.70
-60.40 (-3.07%)
Prev Close
1967.1
Open Price
1950
Volume
146,966
Today Low / High
1892.3 / 1959.5
52 WK Low / High
1225 / 2641
Range
1,811 - 2,002
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 1906.7, with a change of -60.4 (-3.07051%). The expected target range on the NSE is between 1,811 - 2,002. The stock is experiencing a downward trend on the NSE. Investors should be cautious as the price is currently declining.
21 Apr
1,950.00
-2.22%
17 Apr
1,970.00
-0.15%
16 Apr
1,925.60
2.40%
15 Apr
1,913.00
0.66%
11 Apr
1,820.00
2.71%
09 Apr
1,856.85
-7.70%
08 Apr
1,898.65
-1.86%
07 Apr
1,599.00
15.36%
04 Apr
2,059.95
-5.97%
03 Apr
2,028.00
1.36%
02 Apr
1,977.70
-0.01%
01 Apr
1,994.25
-0.83%
28 Mar
2,039.00
-1.92%
27 Mar
1,980.25
1.51%
26 Mar
2,065.00
-3.60%
25 Mar
2,060.00
-0.18%
24 Mar
2,034.00
0.85%
Caplin Point Laboratories Limited Graph
Caplin Point Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Caplin Point Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,906.70, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,906.70 | 1,925.77 | 1,733.19 - 2,118.34 |
| 1,944.83 | 1,555.87 - 2,333.80 | ||
| 1,963.90 | 1,374.73 - 2,553.07 | ||
| Bearish Scenario | 1,906.70 | 1,887.63 | 1,698.87 - 2,076.40 |
| 1,868.57 | 1,494.85 - 2,242.28 | ||
| 1,849.50 | 1,294.65 - 2,404.35 |
Overview of Caplin Point Laboratories Limited
ISIN
INE475E01026
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
159,316
Market Cap
144,931,500,763
Last Dividend
5
Official Website
IPO Date
2014-06-23
DCF Diff
-191.75
DCF
2,119
Financial Ratios Every Investor Needs
Stock Dividend of CAPLIPOINT
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-09-23 | September 23, 24 | 2.5 | 2.5 | 2024-09-23 | 2024-10-30 | |
| 2024-05-31 | May 31, 24 | 2.5 | 2.5 | 2024-05-31 | 2024-06-15 | |
| 2023-09-14 | September 14, 23 | 2.5 | 2.5 | 2023-09-14 | 2023-10-21 | |
| 2023-06-09 | June 09, 23 | 2 | 2 | 2023-06-09 | 2023-08-26 | |
| 2022-09-21 | September 21, 22 | 2 | 2 | 2022-09-22 | 2022-10-29 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1,676.78 Cr | 756.13 Cr | 920.65 Cr | 0.5491 | 73.72 Cr | 16.83 Cr | 722.53 Cr | 457.09 Cr | 59.90 | 618.38 Cr | 0.2726 |
| 2023-03-31 | 1,466.73 Cr | 663.21 Cr | 803.52 Cr | 0.5478 | 63.19 Cr | 0.00 Cr | 452.13 Cr | 376.26 Cr | 49.62 | 497.04 Cr | 0.2565 |
| 2022-03-31 | 1,263.01 Cr | 560.45 Cr | 702.56 Cr | 0.5563 | 59.27 Cr | 22.89 Cr | 385.64 Cr | 299.84 Cr | 39.61 | 433.42 Cr | 0.2374 |
| 2021-03-31 | 1,048.26 Cr | 475.10 Cr | 573.15 Cr | 0.5468 | 53.69 Cr | 16.60 Cr | 313.82 Cr | 242.27 Cr | 32.03 | 352.18 Cr | 0.2311 |
| 2020-03-31 | 863.20 Cr | 416.49 Cr | 446.71 Cr | 0.5175 | 53.01 Cr | 10.39 Cr | 264.37 Cr | 215.01 Cr | 28.42 | 302.27 Cr | 0.2491 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 550.12 Cr | 2,698.12 Cr | 351.29 Cr | 2,315.7100 Cr | 1.97 Cr | -548.15 Cr | 363.04 Cr | 556.76 Cr | 30.81 Cr | 10.48 Cr | 132.64 Cr | 331.2800 Cr |
| 2023-03-31 | 177.56 Cr | 2,191.40 Cr | 284.13 Cr | 1,880.4800 Cr | 5.20 Cr | -172.36 Cr | 288.22 Cr | 489.35 Cr | 22.53 Cr | -14.14 Cr | -472.31 Cr | 268.0000 Cr |
| 2022-03-31 | 456.74 Cr | 1,736.32 Cr | 226.44 Cr | 1,483.9300 Cr | 2.13 Cr | -454.61 Cr | 227.31 Cr | 293.43 Cr | 5.49 Cr | -21.79 Cr | -429.32 Cr | 207.6800 Cr |
| 2021-03-31 | 456.96 Cr | 1,363.61 Cr | 160.25 Cr | 1,185.8216 Cr | 18.39 Cr | -438.57 Cr | 179.00 Cr | 311.93 Cr | 33.20 Cr | 5.70 Cr | -9.87 Cr | 142.8535 Cr |
| 2020-03-31 | 211.64 Cr | 1,125.76 Cr | 169.19 Cr | 947.9142 Cr | 38.61 Cr | -173.03 Cr | 238.23 Cr | 287.56 Cr | 0.00 Cr | 5.23 Cr | -59.67 Cr | 144.3247 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 318.3900 Cr | -320.0400 Cr | -38.0700 Cr | 172.5700 Cr | -38.8600 Cr | 138.7000 Cr | -145.8200 Cr | 457.0900 Cr | -3.1300 Cr | -34.1700 Cr | -74.8200 Cr |
| 2023-03-31 | 271.6500 Cr | -217.8600 Cr | -28.1700 Cr | 77.9000 Cr | 26.8000 Cr | 177.5600 Cr | -193.7500 Cr | 451.3500 Cr | 2.9100 Cr | -30.3200 Cr | -60.9000 Cr |
| 2022-03-31 | 336.7500 Cr | -270.9400 Cr | -40.7100 Cr | 245.5700 Cr | 16.7800 Cr | 452.5000 Cr | -91.1800 Cr | 385.8200 Cr | -16.5600 Cr | -22.6900 Cr | -48.3100 Cr |
| 2021-03-31 | 265.7725 Cr | -5.3597 Cr | -23.9776 Cr | 195.2894 Cr | 231.5888 Cr | 452.3557 Cr | -70.4831 Cr | 313.6185 Cr | -19.4111 Cr | -3.0257 Cr | 59.2298 Cr |
| 2020-03-31 | 44.6770 Cr | -54.5048 Cr | 79.7652 Cr | -32.0611 Cr | 60.9818 Cr | 211.6365 Cr | -76.7381 Cr | 269.4625 Cr | -0.2153 Cr | -32.5263 Cr | -7.0315 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 492.96 Cr | 195.35 Cr | 297.61 Cr | 0.6037 | 146.09 Cr | 138.96 Cr | 18.28 | 193.64 Cr | 0.2819 |
| 2024-09-30 | 483.10 Cr | 188.82 Cr | 294.28 Cr | 0.6091 | 148.00 Cr | 130.80 Cr | 17.22 | 185.43 Cr | 0.2708 |
| 2024-06-30 | 458.96 Cr | 241.59 Cr | 217.37 Cr | 0.4736 | 214.13 Cr | 123.97 Cr | 16.32 | 170.37 Cr | 0.2701 |
| 2024-03-31 | 389.28 Cr | 176.60 Cr | 212.68 Cr | 0.5463 | 112.80 Cr | 121.58 Cr | 13.45 | 162.52 Cr | 0.3123 |
| 2023-12-31 | 435.50 Cr | 190.11 Cr | 245.39 Cr | 0.5635 | 145.58 Cr | 117.20 Cr | 15.43 | 159.46 Cr | 0.2691 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 176.84 Cr | 696.77 Cr | 873.61 Cr | 0.00 Cr | 327.09 Cr | 1,998.82 Cr | 606.47 Cr | 2,924.22 Cr | 349.62 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 790.72 Cr | 0.00 Cr | 0.00 Cr | 790.72 Cr | 0.00 Cr | 0.00 Cr | -2,346.82 Cr |
| 2024-03-31 | 552.74 Cr | 237.98 Cr | 790.72 Cr | 545.31 Cr | 363.04 Cr | 1,892.21 Cr | 556.76 Cr | 2,697.38 Cr | 350.56 Cr |
| 2023-12-31 | -687.40 Cr | 1,374.80 Cr | 687.40 Cr | 0.00 Cr | 0.00 Cr | 687.40 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 137.90 Cr | 589.45 Cr | 727.35 Cr | 458.98 Cr | 336.71 Cr | 1,668.32 Cr | 545.47 Cr | 2,412.84 Cr | 310.37 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 123.97 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 121.59 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 117.20 Cr | 27.80 Cr | 0.00 Cr | 0.00 Cr | 27.80 Cr | 593.71 Cr | 565.91 Cr | 0.00 Cr | 27.80 Cr |
| 2023-09-30 | 114.87 Cr | 23.52 Cr | 0.00 Cr | 0.00 Cr | 23.52 Cr | 565.91 Cr | 542.39 Cr | 0.00 Cr | 23.52 Cr |
| 2023-06-30 | 103.43 Cr | 22.76 Cr | 0.00 Cr | 0.00 Cr | 22.76 Cr | 202.69 Cr | 179.93 Cr | 0.00 Cr | 22.76 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2016-10-19 | October 19, 16 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,744.90 | ₹4,186,497,390,360.00 | ₹1,539,404.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,891.50 | ₹1,564,008,080,155.00 | ₹717,304.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,254.60 | ₹1,101,504,496,478.00 | ₹168,941.00 |
| Mankind Pharma Limited | MANKIND | ₹2,588.40 | ₹1,067,918,241,168.00 | ₹342,053.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,177.40 | ₹980,907,622,968.00 | ₹1,938,682.00 |
| Lupin Limited | LUPIN | ₹2,009.20 | ₹917,330,458,276.00 | ₹966,589.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹845.35 | ₹850,616,530,500.00 | ₹1,860,605.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,201.20 | ₹697,658,929,968.00 | ₹653,310.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,000.40 | ₹597,872,826,000.00 | ₹97,948.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,368.80 | ₹386,259,126,032.00 | ₹2,163,260.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,423.80 | ₹361,224,068,436.00 | ₹163,712.00 |
| Laurus Labs Limited | LAURUSLABS | ₹640.35 | ₹345,310,338,375.00 | ₹1,671,228.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,679.20 | ₹334,664,498,320.00 | ₹44,703.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,202.20 | ₹306,037,994,912.00 | ₹330,131.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,658.70 | ₹258,221,804,814.00 | ₹100,079.00 |
| Piramal Enterprises Limited | PEL | ₹1,039.85 | ₹234,462,986,345.00 | ₹552,041.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,401.40 | ₹227,698,028,558.00 | ₹264,593.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,727.50 | ₹218,187,500,000.00 | ₹13,476.00 |
| Eris Lifesciences Limited | ERIS | ₹1,382.90 | ₹188,299,218,053.00 | ₹81,150.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,136.00 | ₹168,533,566,400.00 | ₹53,273.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹849.65 | ₹167,009,863,405.00 | ₹223,768.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹829.80 | ₹148,625,361,828.00 | ₹383,129.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹915.95 | ₹145,893,560,183.00 | ₹228,298.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,906.70 | ₹144,931,500,763.00 | ₹146,966.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹480.20 | ₹116,469,494,344.00 | ₹1,207,487.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,223.50 | ₹86,706,866,654.00 | ₹3,571.00 |
| FDC Limited | FDC | ₹430.60 | ₹70,106,024,754.00 | ₹67,489.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹712.85 | ₹64,608,888,867.00 | ₹374,808.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹658.10 | ₹64,356,197,871.00 | ₹163,074.00 |
| Strides Pharma Science Limited | STAR | ₹640.75 | ₹59,053,256,433.00 | ₹243,236.00 |
| Innova Captab Limited | INNOVACAP | ₹915.85 | ₹52,409,452,141.00 | ₹37,786.00 |
| Hikal Limited | HIKAL | ₹423.80 | ₹52,254,857,850.00 | ₹371,223.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹152.84 | ₹49,599,942,480.00 | ₹505,473.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹633.90 | ₹44,630,236,620.00 | ₹75,809.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹799.75 | ₹40,562,604,224.00 | ₹101,985.00 |
| Sequent Scientific Limited | SEQUENT | ₹148.17 | ₹37,087,247,340.00 | ₹527,793.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,179.20 | ₹36,041,821,488.00 | ₹10,217.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.90 | ₹35,087,098,650.00 | ₹40,163.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹361.65 | ₹33,007,795,500.00 | ₹101,872.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.91 | ₹29,540,183,967.00 | ₹4,747,370.00 |
| Suven Life Sciences Limited | SUVEN | ₹127.13 | ₹27,723,712,024.00 | ₹173,057.00 |
| Alembic Limited | ALEMBICLTD | ₹105.35 | ₹27,051,965,791.00 | ₹436,085.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹520.70 | ₹25,021,207,514.00 | ₹37,558.00 |
Key Executives
Deputy Chief Financial Officer
Mr. M. Sathya Narayanan
Gender: male
Year Born:
Chief Transformation & Digital Officer
Mr. Thiagaraja Manikandan
Gender: male
Year Born:
Head of Marketing - Latam Business
Mr. Ashok Gorekey Partheeban
Gender: male
Year Born:
Chief Financial Officer
Mr. D. Muralidharan
Gender: male
Year Born:
MD & Whole Time Director
Dr. Sridhar Ganesan
Gender: Not Specified
Year Born: 1955
General Counsel, Company Secretary & Compliance Officer
Mr. G. Venkatram
Gender: male
Year Born: 1982
Chief Operating officer
Mr. Partheeban Vivek Siddarth
Gender: male
Year Born:
FAQs about Caplin Point Laboratories Limited
Who is the CEO of the company?
The CEO is Dr. Sridhar Ganesan.
What is the current market price of the stock?
The current price is ₹1,906.70.
What is the 52-week price range?
The range is ₹1225-2641.
What is the market capitalization of the company?
The market capitalization is ₹14,493.15 crores.
What is the dividend yield?
The dividend yield is 0.26%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 28.13.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Caplin Point Laboratories Limited (ISIN: INE475E01026) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹14,493.15 crores and an average daily volume of 159,316 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹5.